Quva Pharma, Inc., Bloomsbury, NJ

Is Quva Pharma, Inc. an FDA-registered 503B outsourcing facility?

Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Quva Pharma, Inc. in Bloomsbury, NJ, first registered Sep 15, 2017 and most recently registered Oct 23, 2026. FDA lists its last inspection as Apr 4, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Open”.

FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.

Location on FDA’s list
Bloomsbury, NJ
Initial registration
Sep 15, 2017
Most recent registration
Oct 23, 2026
Last inspection
Apr 4, 2025
Form 483 issued at last inspection
Yes
Recall after last inspection
No
Action on last inspection
Open
Intends to compound sterile drugs from bulk substances
Yes
Earlier inspections
FDA notes that an earlier inspection led to a Form 483, warning letter or other action

FDA inspections and actions on record

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as QuVa Pharma, Inc., Bloomsbury, NJ, a 503B facility, with 4 listed actions, including 3 Form 483s and 1 warning letter (2019 to 2025).

Document
Apr 4, 2025Form 483483 issued 04/04/2025fda.gov
Jan 26, 2024Warning letterWarning Letter Issued 01/26/2024FDA copy (archived)
Oct 14, 2022Form 483483 Issued 10/14/2022FDA copy (archived)
May 31, 2019Form 483483 Issued 05/31/2019fda.gov

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists QuVa Pharma, Inc., Bloomsbury, NJ (FEI number 3013931875), matched to this page by exact name, city and state. It lists 4 inspections: 3 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Apr 4, 2025Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30139318751263856
Oct 14, 2022Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30139318751181531
May 31, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30139318751094744
Nov 30, 2017Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30139318751032363

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 18 numbered observations in all, across 4 inspections ending Nov 30, 2017 to Apr 4, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Mar 25, 2025 to Apr 4, 2025: 5 observations

Firm on the cover
QuVa Pharma, Inc., 519 State Route 173, Bloomsbury, NJ 0880 44047
FEI number
3013931875
Establishment type on the cover
Outsourcing Facility This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone nmnber and address above.
FDA district office on the cover
10 Waterview Blvd., 3rd Floor Parsippany, NJ 0705 4
Matched to this page by
FEI number on the cover; linked from actions page, 503B list, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

The accuracy specificity and reproducibility of test methods have not been established.

Specifically,

Your firm did not appropriately qualify the performance qualification, RDI Report-0083, for <Redacted B4> sterility testing method for Cefazolin 3g in l00mL Normal Saline (NS). Your firm did not achieve the percent recovery <Redacted B4> of all challenge microorganisms, specifically P. aeruginosa. There is a non-conformance associated with the performance qualification that states that low recovery was achieved for P. aeruginosa so retesting was performed and that all 3 replicates pass. The raw data sheets show that the method suitability testing was retested multiple times with only the results meeting criteria being reported. The initial test shows results of 33%, 0%, and 0% recovery. The first retest shows results of 54%, 31 %, and 62%. The second retest shows results of 30%, 60%, and an unreported result. The firm has used this method to test for sterility on all lots of Cefazolin in Sodium Chloride compounded at the site.

Observation 2

There is a failure to thoroughly review any unexplained discrepancy and the failure ofa batch or any of its components to meet any of its specifications whether or not the batch has been akeady distributed.

Specifically,

1 ) Sterility out of specification investigations do not include an identification of the microorganism recovered due to destructive methods of the <Redacted B4> testing used. Your firm opened Dev-2383 and sterility OOS-0562 for Phenylephrine HCL 400mcg (50mcg/ml) 10ml in 0.9% Sodium Chloride solution I0ml syringe to investigate a non-sterile event on 2/5/2024. No root cause was identified for this non-sterile event and no remediation actions were taken. The lot was rejected.

3) Your firm's AQL failures for visual inspection do not include corrective actions to address defect

rates found during the inspection process. In addition, your firm's procedure NJ-SOP-QA-001 1 Rev . 20 , "Performin g Acceptabl e Qualit y Limi t Inspections " states , i n part , tha t "..Unless otherwise specified by Quality and Operations Management; operations will repeat I 00% inspection on the units that were not rejected during the initial inspection and document the re­inspection ... ...

Read the full 483 (PDF on fda.gov)

Observation 3

Written procedures for sanitation are not followed.

Specifically,

Your firm did not perform <Redacted B4> cleaning in controlled non-classified formulation areas as required by procedure NJ-SOP-SA-0003, "Cleaning/Disinfection of Compounding Manufacturing Areas". Your firm's cleaning log for Building 2, Room 1408 used for formulation of bulk drug product for further processing does not include <Redacted B4> cleaning documentation until the week of 3/24/2025. Your firm only documented a <Redacted B4> clean of this room. In addition, conditions of the room were found to be in disrepair including build up of debris in the floor scale, apparent residue splashes on the ceiling and discoloration from potential dust build up on the air return grate that is located above where weighing and mixing occurs. This room is constructed with a drop tile ceiling that does not lend itself to be easily cleaned.

Observation 4

The statistical quality control criteria fail to include appropriate rejection levels.

Specifically,

Your firm has a lot <Redacted B4> overall reject limit for defects found in the visual inspection process that is not scientifically or statistically justified. Individual defect categories do not have reject limits. Your firm does not open deviations or events until the {b) reject rate is reached. During production of Cefazolin Sodium PF 2mg, 20mL in SWFI syringe, lot <Redacted B4> your visual inspection process rejected 9.6% of <Redacted B4> syringes including (bH \ejects for liquid past the plunger. These liquid past the plunger units are major defects, as defined by procedure NJ-SOP-QA-0011 , "Performing Acceptable Quality Limit Inspections". The defect rate was not investigated or corrected to prevent these defects from occurring during compounding. Your firm has opened thirteen deviations for reject rates exceeding limits <Redacted B4> of the batch since 10/14/2022.

Since 11/7/2024, your firm has not investigated approximately <Redacted B4> batches of drug product that have total reject rates exceeding your <Redacted B4> alert limit for total rejects. These batches include: ...

Read the full 483 (PDF on fda.gov)

Observation 5

Employees engaged in the manufacture, processing and packing of a drug product lack the training required to perform their assigned functions.

Specifically,

A) Your firm's syringe visual inspection qualification kit used during visual inspection qualification testing is not representative of the visual inspection process. The qualification kits used contain a Inix of syrinoe sizes ranging from <Redacted B4> to <Redacted B4>. The 41 <Redacted B4> unit kits contain a Inix of <Redacted B4> selected critical <Redacted B4> selected major defects, and <Redacted B4> defects. This results in a test kit reject rate of a proximately <Redacted B4>. . In addition, <Redacted B4> lof the <Redacted B4>~ <Redacted B4> minor defects in the kit contain the same defect for <Redacted B4>

B) Your firm's qualification testing for visual inspection does not adequately simulate fatigue. The <Redacted B4> unit kit must be completed within <Redacted B4> and is repeated in <Redacted B4> for initial qualification. The operators routinely inspect for <Redacted B4> during production prior to taking an eye break.

Inspection Aug 16, 2022 to Oct 14, 2022: 5 observations

Firm on the cover
QuVa Pharma, Inc., 519 State Route 173, Bloomsbury, NJ 08804-4047
FEI number
3913931875
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
New Jersey District Office 10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
Matched to this page by
firm name, city and state on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed. Specifically,

A) No documented review was performed when mold was recovered on an operator <Redacted B4> plate sample taken on 06/29/2022 after ISO 5 operations in Clean Room <Redacted B4> and the clean room experienced elevated temperature and relative humidity excursions beyond the set alrm points. The mold recovery on 06/29 was the third mold recovery on <Redacted B4> plates in three (3) months. In addition, a documented risk assessment was not performed on products produced after the mold recoveries in the same cleanroorns or ISO S hoods. Mold was recovered on operators was <Redacted B4> after ISO 5 operations (listed below) and the product was released and/or the bulk material used to produce Compounded Sterile Product (CSP) which were released between 05/26/2022-07/26/2022.

Bulk Lot# (Expiration Date)

Date Compounded

Mold Identification on one (1) Hand (Colony Forming Units (CFU#))

Product (Bulk /CSP)

CSP Lot# (Expiration Date)

Fentanyl Citrate, PF, 10 mcg/mL in NS 3 L Bulk< Bag (Bulk<)

Lot# <Redacted B4> (05/12/2022)

Rhizopus oryzae (1)

NIA ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions. Specifically,

Your firm 's environmental and personnel monitoring program does not include sampling of all potential routes of microbial contamination. For example:

A) On 08/16/2022, during our observation of sterile filling of Epinephrine, Preservative Free (PF), 1 0mcg/ml in 10ml Dextrose 5% in <Redacted B4> (D5W) Syringe, Lot'# <Redacted B4> , Expiration Date: 11/14/2022 within the ISO 5 <Redacted B4> Laminar Air Flow <Redacted B4> syringe filling machine (Equipment ID: <Redacted B4>, located in Cleanroom ~(ISO 7), we observed the operator place their upper left side of the body (including head, chest, and sleeves) into the ISO 5 area within the syringe filler. However, only <Redacted B4> samples are collected at the completion of each production lot. We also witnessed the operator open the Zone u and Zone <Redacted B4> doors (located behind the bulk product source bag) of the <Redacted B4> fill machine into the ISO 7 area; however, no surface samples are collected from the Zone <Redacted B4> Zone <Redacted B4>doors. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess. Specifically,

Your firm's visual inspection procedure utilized during Inspection, Labeling and Packaging (ILP) of sterile products, are deficient for the following reasons:

A) The <Redacted B4> and defect <Redacted B4> that is used to train and qualify visual inspection operators and AQL visual inspectors do not include representative defects for "debris" and "excessive liquid between plunger ribs". For example, your firm categorizes "particulates" and "debris" as two different defects to identify during <Redacted B4> . The defect <Redacted B4> used to qualify operators for visual inspection includes seed material for particulates such as <Redacted B4> , <Redacted B4>, <Redactedb B4>, and <Redacted B4> ·; there are no seed materials or examples representative of debris in the defect <Redacted B4> or defect <Redacted B4> respectively. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel. Specifically,

A) Durin g review of user access rights for the <Redacted B4>, Equipment ID: <Redacted B4> in Buildinig <Redacted B4> which are used to test the <Redacted B4> of the <Redacted B4> process bulk, it was observed that all operators access the software with the <Redacted B4> and share a common usemame and password. We also observed that the <Redacted B4> function for the results was enabled for the <Redacted B4> . Additionally, the <Redacted B4> equipment ID is not recorded in the Batch Production Records.

the 15 4 where results generated from the (o) (4) pennits users to delete files and folders.

C) During walkthrough of the QC laboratory and review of data in the <Redacted B4> software, we observed that Senior Chemist ( <Redacted B4> who routinely conducts analytical testing of finished sterile products, and raw materials, had <Redacted B4> roles assigned and has final data review and approve privileges in <Redacted B4> enabled. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established or followed. Specifically,

A) Smoke studies conducted on 09/08-09/ 10/2021 in the ISO 5 <Redacted B4> syringe filler (Equipment ID: NJ <Redacted B4> and on 02/24/2022 in the ISO 5 LAF Hood (Equipment ID: NJ-LAF - <Redacted B4> are inadequate. Specifically, during the smoke studies, the <Redacted B4> system was not turned on during dynamic study to demonstrate that the <Redacted B4> system does not alter or impede the unidirectionality of air from the HEPA filter to the ISO 5 area of the <Redacted B4> syringe filler or laminar air flow hoods where products are aseptically processed.

B) During observation of sterile production activities, the following deficiencies in aseptic behaviors and gowning were observed:

i. ...

Read the full 483 (PDF on fda.gov)

Inspection May 7, 2019 to May 31, 2019: 6 observations

Firm on the cover
QuVa Pharma, Inc., 519 State Route 173, Bloomsbury, NJ 08804-404 7 TYPE ESTABUSHMENT tNSPECTED Outsourcing Facility
FEI number
3013931875
FDA district office on the cover
10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

The quality control unit lacks responsibi lity to approve and reject all procedures or specifications impacting on the identity, strength, quality and purity of drug products.

Specifically,

A) <Redacted B4> missing media <Redacted B4> 10 mL syringe units of <Redacted B4> total units processed during aseptic process simulation conducted on 09/20/2018 for Lot #0920 18LR were not incubated and tested for microbial growth as part of the performance qualification for Building manufacturing Suite/Cleanroorrf'..j ln addition, the l'ire syringes used to prime and calibrate equipment were not incubated and tested for microbial growth. No explanation was documented for the missing media fill units.

B) <Redacted B4> missing media fill 60 mL syringe units of <Redacted B4> 1 total units processed during aseptic process simulation conducted on 09/19/2018 for Lot #09 I 9 l 8KS were not incubated and test <Redacted B4> or microbial growth as part of the perfonnance qualification for Building':3Manufacturing Suite/Cleanroom In addition, the <Redacted B4> syringes used to prime and calibrate equipment were not incubated and tested for microbial growth. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Written records of investigation of a drug complaint do not include the findings of the investigation and the follow-up.

OAre,ssueo

Specifically,

Complaint 0115, Event Date: 02/04/2019 was received due to particulates being observed for multiple lots ( syringes) of Sodium Bicarbonate lmeq/lmL, 50 mL syringes, including for the following only lot information provided: Lot #30001883, Exp: 04/03/2019. The complaint investigation report determined that sodium biocarbonate likely crystallized in transit under extreme conditions and is not associated with production ·error. However, the investigation did not include review of drug product stability and formulation, retain samples, or identification of the particulate matter. In addition, shipping studies have not been performed to determine the effects of shipment and transit conditions on the compounded drug product.

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include validation of the aseptic process.

Specifically,

There is no standard operating procedure or batch record instructions for the number of IV bag units allowed within the ISO 5 hood at a time. For example:

<Redacted B4> units were compounded as part of Oxytocin II Units added to <Redacted B4> ml 0.9% Sodium Chloride solution bag, Lot# 30003332, Exp. Date: 07/23/2019. However, there is no documentation or batch record instructions for the number of units allowed within the ISO 5 hood during each dosing set of the total <Redacted B4> · units processed.

Observation 4

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

A) Hard-to-reach areas within the ceilings ofISO 7 Cleanroom suites are not evaluated and sampled as part of the environmental monitoring (EM) program. T his includes the lack

( evaluation for crevices of the wireless router box . mounted on the ceiling of ISO 7 Manufacturing Suite/Cleanroom <Redacted B4>

8) EM sampling locations within the ISO 5 hood area are not defined within standard operating procedures, batch record instructions or EM sampling worksheets.

Observation 5

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that conform to appropriate standards of identity, strength, quality and purity.

Specifically,

A) Reach-in incubator NJ-INC-0006, with Operating Range <Redacted B4>: -degrees Celsius, is used to incubate environmental monitoring (EM) and personnel monitoring (PM) samples. However, it has not been evaluated to determine whether the loaded chamber works within-the-specified limits of temperature through-out the chamber. The effect of opening doors at different lengths of time, and the effect of a power failure on the incubator's ability to get back into the temperature profile have not been evaluated either. Temperature mapping studies were conducted using empty incubator conditions.

B) Walk-in refrigerator NJ-REF-0006, with Operating Range <Redacted B4> degrees Celsius, is used to store finished product lots requiring refrigerated conditions prior to shipment, including that of: Lidocaine I% Bicarbonate I 0 mL syringes and Vancomycin 1.25g -250 mL bags. ...

Read the full 483 (PDF on fda.gov)

Observation 6

Establishment of the reliability of the component supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.

Specifically,

Test results of Active Pharmaceutical Ingredients (APis) suppliers used for compounding bulk drug products have not been appropriately validated at appropriate intervals. This includes the lack of qualification for related substances, organic impurities and/or residual solvents test results received for:

A) Norepinephrine Bitartate API, Expiry Date: five (5) years

B) Phenylephrine HCL API, Retest Date: five (5) years

C) Epinephrine API, Retest Date: two (2) years

Inspection Nov 13, 2017 to Nov 30, 2017: 2 observations

Firm on the cover
, 519 State Route 173 QuVa Pharma, Inc ., Bloomsbury, NJ 08804-4047
FEI number
3013931875
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Written procedures for sanitation are not followed.

Specifically, no cleaning was performed as per SOP NJ-SOP-SA-0003, Section 4.4, which states <Redacted B4> cleaning of the Aseptic Processing Areas (cleanrooms and gowning/ante-rooms) shoul

d occur <Redacted B4> is used for pr oduction activiti e s". However , Heparin 1 unit/ mL 3L Bulk, Lot <Redacted B4> compou nding date 10/25/17 was not documented in the <Redacted B4> cleaning log for ISO-7 cleanroom <Redacted B4> .

Observation 2

The batch production and control records are deficient in that they are not an accurate reproduction of the appropriate master production or control record and checked for accuracy, dated, and signed.

Specifically, the <Redacted B4> noted in step 8 of the approved batch record for Heparin lunit/mL 3L Bulk, Lot <Redacted B4> compounded on 11/06/17, states to <Redacted B4> with <Redacted B4>. However, there was no documentation in the batch record to justify that was used for the <Redacted B4>, not <Redacted B4>. This lot was approved and released by Quality on 11/15/17 for further packaging into individually dosed syringes at your Sugar Land, TX facility.

GLP-1 records in this index

No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Quva Pharma, Inc.). That is not a finding beyond this index’s search.

The Quva Pharma, Inc. pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.

FDA’s 503B list also names Quva Pharma, Inc., Sugar Land, TX. Each is a separate listing with its own records; a similar name does not show they are the same firm.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.